Wolverine Trading LLC Makes New Investment in Ironwood Pharmaceuticals, Inc. (NASDAQ:IRWD)

Wolverine Trading LLC purchased a new position in shares of Ironwood Pharmaceuticals, Inc. (NASDAQ:IRWD) during the 3rd quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm purchased 12,747 shares of the biotechnology company’s stock, valued at approximately $51,000.

Other large investors have also recently made changes to their positions in the company. Charles Schwab Investment Management Inc. raised its stake in shares of Ironwood Pharmaceuticals by 23.7% during the third quarter. Charles Schwab Investment Management Inc. now owns 1,904,271 shares of the biotechnology company’s stock worth $7,846,000 after acquiring an additional 364,841 shares in the last quarter. Weiss Asset Management LP purchased a new position in shares of Ironwood Pharmaceuticals during the third quarter worth approximately $893,000. Robeco Institutional Asset Management B.V. raised its stake in shares of Ironwood Pharmaceuticals by 1,293.6% during the third quarter. Robeco Institutional Asset Management B.V. now owns 380,960 shares of the biotechnology company’s stock worth $1,570,000 after acquiring an additional 353,624 shares in the last quarter. Connor Clark & Lunn Investment Management Ltd. increased its stake in shares of Ironwood Pharmaceuticals by 150.7% in the third quarter. Connor Clark & Lunn Investment Management Ltd. now owns 126,289 shares of the biotechnology company’s stock worth $520,000 after buying an additional 75,917 shares during the period. Finally, Walleye Capital LLC increased its stake in shares of Ironwood Pharmaceuticals by 264.2% in the third quarter. Walleye Capital LLC now owns 280,299 shares of the biotechnology company’s stock worth $1,155,000 after buying an additional 203,331 shares during the period.

Insider Buying and Selling at Ironwood Pharmaceuticals

In other news, CFO Sravan Kumar Emany sold 11,001 shares of the business’s stock in a transaction on Monday, November 18th. The shares were sold at an average price of $4.08, for a total transaction of $44,884.08. Following the sale, the chief financial officer now owns 309,572 shares in the company, valued at approximately $1,263,053.76. The trade was a 3.43 % decrease in their position. The sale was disclosed in a filing with the SEC, which is accessible through the SEC website. Insiders own 12.90% of the company’s stock.

Analysts Set New Price Targets

Several brokerages recently commented on IRWD. Leerink Partnrs raised shares of Ironwood Pharmaceuticals to a “hold” rating in a research note on Monday, September 9th. StockNews.com downgraded shares of Ironwood Pharmaceuticals from a “strong-buy” rating to a “buy” rating in a research note on Tuesday, November 12th. Finally, Leerink Partners began coverage on shares of Ironwood Pharmaceuticals in a research note on Monday, September 9th. They issued a “market perform” rating and a $5.00 target price on the stock. Three equities research analysts have rated the stock with a hold rating and four have assigned a buy rating to the stock. Based on data from MarketBeat, the company presently has an average rating of “Moderate Buy” and an average target price of $10.40.

Ironwood Pharmaceuticals Trading Up 2.3 %

Shares of Ironwood Pharmaceuticals stock opened at $3.53 on Wednesday. The company’s fifty day simple moving average is $3.99 and its two-hundred day simple moving average is $4.95. The company has a market cap of $564.90 million, a P/E ratio of -117.67 and a beta of 0.41. Ironwood Pharmaceuticals, Inc. has a 12-month low of $3.06 and a 12-month high of $15.70.

Ironwood Pharmaceuticals (NASDAQ:IRWD) last issued its quarterly earnings data on Thursday, November 7th. The biotechnology company reported $0.02 earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of $0.09 by ($0.07). The company had revenue of $91.60 million for the quarter, compared to analysts’ expectations of $91.22 million. Ironwood Pharmaceuticals had a negative net margin of 0.65% and a negative return on equity of 0.96%. The firm’s revenue for the quarter was down 19.4% compared to the same quarter last year. During the same period in the previous year, the firm posted $0.12 earnings per share. Analysts predict that Ironwood Pharmaceuticals, Inc. will post 0.08 EPS for the current fiscal year.

Ironwood Pharmaceuticals Profile

Ironwood Pharmaceuticals, Inc, a healthcare company, focuses on the development and commercialization of gastrointestinal (GI) products. It markets linaclotide, a guanylate cyclase type-C (GC-C) agonist for the treatment of adults suffering from irritable bowel syndrome with constipation or chronic idiopathic constipation under the LINZESS name in the United States, Mexico, Japan, Saudi Arabia, and China, as well as under the CONSTELLA name in the Canada and European countries.